Loading...
NPI 1164775862 · Birmingham, AL · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Southern Lab Partners, LLC is a clinical medical laboratory provider located in Birmingham, Alabama. This profile covers 43 Medicare and 76 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Southern Lab Partners, LLC |
| Address | 2732 7th Ave S |
| City | Birmingham |
| State | AL |
| ZIP | 35233 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | October 18, 2012 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicaid | $14.4M |
| Medicare | $5.4M |
SOUTHERN LAB PARTNERS, LLC is a clinical medical laboratory with an NPI enumerated 2012-10-18 (~14 years ago), indicating over a decade of presence in the market which supports an established laboratory operation and sustained payer relationships. Its Medicare lifetime revenue is $5.4M while Medicaid lifetime revenue is $14.4M, signaling a materially larger footprint in the Medicaid market versus Medicare. The provider’s Medicare revenue is highly concentrated: the precomputed top 3 Medicare codes account for 98.9% of its Medicare revenue, driven predominantly by K1034 which alone generates $5.2M (95.2% of Medicare revenue). That concentration implies a business model on Medicare that is overwhelmingly dependent on a single test-type activity. Medicaid billing is more diversified relative to Medicare but still concentrated: the precomputed top 3 Medicaid codes account for 62.8% of its Medicaid revenue, with large volumes in multiplex amplified probe and respiratory virus codes like 87798 ($4.2M, 29.7% of Medicaid revenue), 87633 ($3.4M, 24.0%) and 87801 ($1.3M, 9.2%), indicating a service line focused on high-volume infectious disease and respiratory pathogen testing for Medicaid payors. On competitive standing, SOUTHERN LAB PARTNERS is an extreme outlier nationally for K1034 (ranks #90 of 30143 providers nationally; 100th percentile), which signals unusually high Medicare volume for that code compared with peers; by contrast its other Medicare codes (G0482, G0480, etc.) are in typical-to-high percentiles but not exceptional. In the state Medicaid market the provider posts top-tier volumes for many infectious disease and multiplex testing codes: it ranks in the top decile or better for key codes (e.g., 87798 #6 of 57, 87633 #7 of 98, 87801 #6 of 92), and holds several #1 in-state ranks for specialized codes (e.g., 87149 and 87561 ranked #1 of small peer sets), consistent with a major regional player for molecular and multiplex infectious testing. The code mix (dominant K1034 on Medicare; high-volume amplified nucleic acid/multiplex codes on Medicaid such as 87798, 87633, 87801, and substantial U0004 and 87502 activity) indicates the lab operates high-throughput diagnostic and multiplex molecular platforms and likely focuses on respiratory and infectious disease panels rather than broad anatomic pathology or routine wellness testing. Given the extreme concentration in a single Medicare code versus a broader but still concentrated Medicaid profile, the provider’s financial exposure differs by payer: Medicare results could be vulnerable to reimbursement or coding shifts for K1034, while Medicaid revenue appears anchored in a portfolio of molecular panel services across many respiratory and infectious codes. Several Medicaid codes are flagged as “notably above typical” or top-ranked in-state (e.g., 87149 and 87561 at #1 in-state), reinforcing that the lab is a leading in-state provider for certain specialized molecular assays and likely competes at scale in state Medicaid contracting for infectious disease testing.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
43 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 433,440 | $10 | $5.2M |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 730 | $190 | $139.2K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 560 | $110 | $62.3K |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 260 | $60 | $15.5K |
| 80053 | The lab analyst performs a comprehensive metabolic panel, or CMP test in which he measures the blood level of 14 chemicals the code descriptor lists for the panel. | 420 | $10 | $4.2K |
| 85025 | A complete blood count (better known as a CBC) is a blood test request by a doctor that provides detailed information about various types of cells in a patient's blood. Usually a pathologist or a… | 460 | $10 | $3.6K |
| 82306 | The lab analyst measures the vitamin D level, typically on a serum specimen. This analyte, commonly known as vitamin D, is not really a vitamin, but is an important steroid hormone that is produced… | 120 | $30 | $3.6K |
| 84443 | The lab analyst performs a test to measure the amount of thyroid–stimulating hormone (TSH), a hormone produced in the pituitary gland that helps regulate thyroid function. The typical specimen is the… | 220 | $20 | $3.5K |
| 80061 | The lab analyst performs a lipid panel test in which he measures the blood level of cholesterol and fats called triglycerides in the blood. | 230 | $10 | $3K |
| 87086 | Culture, bacterial; quantitative, colony count, urine. | 340 | $10 | $2.7K |
Showing 1–10 of 43
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 43 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
76 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 30,340 | $140 | $4.2M |
| 87633 | The lab analyst performs a test to identify a respiratory virus using amplified nucleic acid probe technique. He may also use a multiplex reverse transcription technique. The provider does this for… | 17,360 | $200 | $3.4M |
| 87801 | The lab analyst performs a test for multiple infectious agents using amplified nucleic acid probe technique. | 20,200 | $60 | $1.3M |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by… | 15,710 | $60 | $942.7K |
| 87502 | The lab analyst performs a test to determine the presence of multiple types or subtypes of influenza virus through nucleic acid detection using multiplex amplified probe technique and possibly… | 14,760 | $40 | $634.8K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 4,690 | $130 | $623.1K |
| 87507 | The lab analyst performs a test to detect 12 to 25 types or subtypes of a pathogen, such as Clostridium difficile, E. coli, Salmonella, Shigella, norovirus, Giardia, that affects the gastrointestinal… | 2,710 | $180 | $476.8K |
| 87581 | The lab analyst performs a test for Mycoplasma pneumonia, a bacteria, using amplified nucleic acid probe technique. | 19,020 | $30 | $475.4K |
| 87149 | The lab analyst performs an analysis using direct DNA or RNA probe technique on a previously isolated and identified organism to categorize the organism more specifically, such as to the taxonomic… | 15,860 | $20 | $333.1K |
| 87561 | The lab analyst performs a test for Mycobacterium avium intracellulare, MAI, using amplified nucleic acid probe technique. Mycobacteria are bacteria, sometimes called acid fast bacteria because of… | 12,070 | $30 | $301.7K |
Showing 1–10 of 76
How this provider's Medicaid billing volume and revenue compare to other Alabama providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Alabama median
76 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 6 | 60 | 1,260 | $60 | $1.2M |
| 87633 | The lab analyst performs a test to identify a respiratory virus using amplified nucleic acid probe technique. He may also use a multiplex reverse transcription technique. The provider does this for… | 7 | 100 | 470 | $130 | $1.2M |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by… | 4 | 20 | 10,040 | $40 | $825.9K |
| 87507 | The lab analyst performs a test to detect 12 to 25 types or subtypes of a pathogen, such as Clostridium difficile, E. coli, Salmonella, Shigella, norovirus, Giardia, that affects the gastrointestinal… | 3 | 10 | 1,020 | $110 | $784.5K |
| 87591 | The lab analyst performs a lab test for Neisseria gonorrhoeae, also called GC, using amplified nucleic acid probe technique. | 13 | 40 | 450 | $20 | $591.3K |
| 87491 | The lab analyst performs a test for Chlamydia trachomatis using amplified nucleic acid probe technique. | 19 | 40 | 460 | $20 | $584.1K |
| 87661 | The lab analyst performs a test for Trichomonas vaginalis using nucleic acid amplified probe technique. | 22 | 40 | 1,540 | $10 | $397.4K |
| 87581 | The lab analyst performs a test for Mycoplasma pneumonia, a bacteria, using amplified nucleic acid probe technique. | 6 | 40 | 1,440 | $20 | $372.1K |
| 87801 | The lab analyst performs a test for multiple infectious agents using amplified nucleic acid probe technique. | 6 | 90 | 500 | $40 | $303.6K |
| 87486 | The lab analyst performs a test for Chlamydia pneumoniae using amplified nucleic acid probe technique. Chlamydia pneumoniae also known as TWAR, Taiwan Acute Respiratory agent, commonly causes mild… | 10 | 40 | 2,000 | $20 | $273.5K |
Showing 1–10 of 76
Other providers in the same ZIP code as Southern Lab Partners, LLC, ranked by combined Medicare and Medicaid revenue.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.